3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
6
Uterine Cervical Neoplasms
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous-Cell Non-Small-Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Gastrointestinal Neoplasms
1
GastroEsophageal Cancer
1
Gastric or Gastroesophageal Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
162
Carboplatin
144
Paclitaxel
125
Cyclophosphamide
93
130-nm albumin-bound paclitaxel
66
Capecitabine
63
Gemcitabine
54
Doxorubicin
49
Albumin-Bound Paclitaxel
45
Taxes
42
atezolizumab
40
Cisplatin
38
Nivolumab
34
sacituzumab govitecan
32
olaparib
32
Epirubicin
32
Docetaxel
28
eribulin
27
Specimen Handling
26
Bevacizumab
26
durvalumab
25
camrelizumab
23
Drug Therapy
22
Biopsy
22
Magnetic Resonance Spectroscopy
21
toripalimab
18
Radiotherapy
17
spartalizumab
16
Everolimus
15
fludarabine
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Triple Negative Breast Neoplasms
×
bemarituzumab
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled